These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 29129292)

  • 1. Targeting myeloid cells in the tumor sustaining microenvironment.
    Schupp J; Krebs FK; Zimmer N; Trzeciak E; Schuppan D; Tuettenberg A
    Cell Immunol; 2019 Sep; 343():103713. PubMed ID: 29129292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.
    Awad RM; De Vlaeminck Y; Maebe J; Goyvaerts C; Breckpot K
    Front Immunol; 2018; 9():1977. PubMed ID: 30233579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
    Parker KH; Beury DW; Ostrand-Rosenberg S
    Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.
    Fernández A; Oliver L; Alvarez R; Fernández LE; Lee KP; Mesa C
    Hum Vaccin Immunother; 2014; 10(11):3251-60. PubMed ID: 25483674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction.
    Alvarez R; Oliver L; Valdes A; Mesa C
    Semin Oncol; 2018 Jan; 45(1-2):84-94. PubMed ID: 30318088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
    Ostrand-Rosenberg S; Sinha P; Beury DW; Clements VK
    Semin Cancer Biol; 2012 Aug; 22(4):275-81. PubMed ID: 22313874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
    Tuettenberg A; Steinbrink K; Schuppan D
    Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid cell heterogeneity in cancer: not a single cell alike.
    Kiss M; Van Gassen S; Movahedi K; Saeys Y; Laoui D
    Cell Immunol; 2018 Aug; 330():188-201. PubMed ID: 29482836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
    Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
    Front Immunol; 2018; 9():2250. PubMed ID: 30349530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid-Derived Suppressor Cells and Proinflammatory Cytokines as Targets for Cancer Therapy.
    Atretkhany KN; Drutskaya MS
    Biochemistry (Mosc); 2016 Nov; 81(11):1274-1283. PubMed ID: 27914453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy.
    Di Mitri D; Toso A; Alimonti A
    Clin Cancer Res; 2015 Jul; 21(14):3108-12. PubMed ID: 25967145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.
    Kalathil SG; Thanavala Y
    Cell Immunol; 2021 Mar; 361():104280. PubMed ID: 33445053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in understanding regulatory myeloid cells.
    Romano A; Vetro C; Adriani M
    Cancer Biol Ther; 2011 Jun; 11(11):923-6. PubMed ID: 21474999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuning the Tumor Myeloid Microenvironment to Fight Cancer.
    Jahchan NS; Mujal AM; Pollack JL; Binnewies M; Sriram V; Reyno L; Krummel MF
    Front Immunol; 2019; 10():1611. PubMed ID: 31402908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDSCs in cancer: Conceiving new prognostic and therapeutic targets.
    De Sanctis F; Solito S; Ugel S; Molon B; Bronte V; Marigo I
    Biochim Biophys Acta; 2016 Jan; 1865(1):35-48. PubMed ID: 26255541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.